

**Enhancement of Peptide Medical Business**  
**<Sekisui Medical and JITSUBO sign a joint development contract>**

March 2, 2011  
SEKISUI MEDICAL CO., LTD.  
JITSUBO CO., LTD.

SEKISUI MEDICAL CO., LTD. (President & CEO: Mutsumi Fukuda, hereinafter “Sekisui Medical”) and JITSUBO CO., LTD. (President & CEO: Tomio Nagano, hereinafter “JITSUBO”) have started a joint project to expand their peptide business. JITSUBO leads the world in the development of Molecular Hiving Technology (hereinafter “MH technology”), and the two companies signed a joint development contract last December to commercialize this technology in accordance with GMP (Good Manufacturing Practice).

MH technology is a new and highly practical method, for which JITSUBO holds a patent, that uses “liquid phase peptide synthesis” (LPPS) to produce peptide compounds. There are two ways to synthesize peptide compounds; these are the above-mentioned LPPS and “solid phase peptide synthesis” (SPPS). Generally, SPPS is costly, and it is suitable for small scale preparation. On the other hand, LPPS is very useful in large scale production. However, it does not do well in the preparation of long-chained peptide compounds.

This MH technology will enable a reduction in the amount of raw materials and it will also be advantageous in allowing the easier application of GMP by using solid-liquid separation in the process of chaining amino acids. Thus, this MH technology will be a useful one in drug development.

Sekisui Medical will introduce this MH technology at the Asia TIDES exhibition (3/2~3/4) and at CPhI Japan (4/18~4/20).

Company overview

1) Sekisui Medical

President & CEO : Mutsumi Fukuda

Address : 13-5, Nihombashi 3-chome, Chuo-ku, Tokyo, Japan

Business : Diagnostics Reagents, Medical Devices, Pharmaceutical & Fine Chemicals and  
ADME&Tox.Research

Capital : 1,275 million yen (for March 31, 2010)

2) JITSUBO

President & CEO : Tomio Nagano

Address : 24-16, Nakamachi 2-chome, Koganei-city, Tokyo, Japan

Business : Synthesis of Peptide Compounds

Capital : 60 million yen (for March 31, 2010)

Press Contact

SEKISUI MEDICAL CO., LTD.

General Affairs Group, General Affairs & Personnel Department

Fax : +81-3-3278-8774